Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Gideon M. Hirschfield, Harinder Chera et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 186
Proof of efficacy for Seladelpar, a selective PPAR-δ agonist, in patients with primary biliary cholangitis non-responsive to ursodeoxycholic acid: results of an international Phase 2 randomised controlled clinical studyGideon M. Hirschfield, DE Jones, Pol Boudes et al.|Journal of Hepatology|2017Cited by 1